In the meantime, UBS downgraded its Coherus Biosciences Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Monday, Coherus Biosciences Inc [NASDAQ:CHRS] saw its stock fall -5.36% to $1.06. Over the last five days, the stock has gained 26.81%. Coherus Biosciences Inc shares have fallen nearly -23.19% since the year began. Nevertheless, the stocks have fallen -50.70% over the past one year. While a 52-week high of $2.43 was reached on 01/06/25, a 52-week low of $0.66 was recorded on 04/09/25. SMA at 50 days reached $0.9874, while 200 days put it at $1.1906.
Levels Of Support And Resistance For CHRS Stock
The 24-hour chart illustrates a support level at 1.0167, which if violated will result in even more drops to 0.9733. On the upside, there is a resistance level at 1.1067. A further resistance level may holdings at 1.1533. The Relative Strength Index (RSI) on the 14-day chart is 57.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1701, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 19.21%. Stochastics %K at 90.40% indicates the stock is a selling.
How much short interest is there in Coherus Biosciences Inc?
A steep rise in short interest was recorded in Coherus Biosciences Inc stocks on 2025-03-31, growing by 1.72 million shares to a total of 32.49 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 30.77 million shares. There was a rise of 5.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
